Between April 2024 and March 2025, our teams — working closely with partners across Africa and Asia — continued to reach some of the most vulnerable communities with protection and support against malaria. 

Here’s a snapshot of what we accomplished together this year: 

• Helped deliver 4.7 million protective nets to families
• Provided over 14.5 million simple tests that help identify malaria quickly
• Supported treatment for over 13 million people who were diagnosed with malaria
• Made sure over 100 million preventive treatments reached children during the months when malaria risk is highest. 

These achievements reflect not just our reach, but the strength of our partnerships and our commitment to delivering support where it’s needed most. 

Much of this work is made possible by philanthropy. Flexible funding is especially important for reaching children with preventive treatment, which relies on community-level delivery. We work hard to ensure everything we do is carefully monitored, well-run, and held to high standards. 

At the same time, we’re working with high-burden countries towards the achievement of long-term goals – and the elimination of malaria. Our research and learning inform national and global decisions about the best ways to protect people from malaria and how to integrate malaria prevention into wider health services. 

Looking ahead, we’re building on this momentum — expanding our collaborations, exploring new approaches, and through our 2025–2028 strategy, focusing on sustainable, locally-led partnerships. 

But maintaining this progress requires ongoing support. Funding gaps remain, especially in prevention and early detection. Every donation makes a meaningful difference. Your support helps turn nets, tests and treatments into real protection — and turns that protection into lives saved. 

Why give flexible funding to Malaria Consortium? 

Flexible funding lets Malaria Consortium act where the need is greatest, not just where a grant allows. It fills urgent gaps, supports communities quickly and keeps us focused on delivering real impact. This year, that flexibility proved its worth: when sudden funding cuts threatened malaria programmes, our flexible funds provided a crucial bridge that kept essential work going until new financing was secured. 

It also enables us to scale up interventions we know are effective, directing resources to high-impact solutions, like Seasonal Malaria Chemoprevention, as soon as the evidence is clear. Flexible funding supports ongoing research too, allowing us to continually test, refine and validate our approaches, so our work remains rigorously evidence backed. And because it gives us the room to innovate, adapt quickly and respond to real-time needs, it ultimately improves cost-effectiveness—ensuring every pound goes where it can save the most lives. 

Our current funding gap 

Malaria remains one of the most tractable global health challenges: interventions are well-tested, scalable, and relatively neglected compared to their potential to save lives and strengthen health systems. 

To maintain our current programmes into next year and keep reaching the same number of children and families we aim to close an estimated funding gap of US$49 million. 

This funding ensures uninterrupted delivery of proven, cost-effective preventive treatments for malaria, including supporting the scale up of the malaria vaccine. It will increase our ability to find and reach zero-dose and under-immunised children against common childhood diseases and help us to provide testing and referral for more women at risk of cervical cancer as well as help us build resilience to climate-related health shocks in communities most vulnerable to their affects.  

To expand our activities and impact — reaching more children with preventive care, strengthening early detection, and helping countries adapt to rising malaria risks — we aim to raise an additional US$49 million over the coming months. These are programmes we are ready to start or scale, but currently constrained by available funding. 

What we can do with marginal funding 

We know many supporters — including those in the EA community — want to understand exactly what additional funding enables. Here is what marginal contributions can unlock: 

An additional US$10,000 will enable us to:  

• Purchase 75 Rapid Diagnostic tests - simple diagnostic tests that allow community health workers to identify and treat malaria quickly
• Test over 33,000 people for malaria
• Train 570 community distributors to deliver preventative malaria medicine to young children in their local area
• Meet high-value last-mile operational needs that often go unfunded but are essential for programme efficiency and evaluation 

An additional US$100,000 will enable us to:  

• £100,000 could enable expansion of prevention or diagnosis services into new high-burden communities where malaria cases remain high but coverage is low – directly reducing disease burden.
• It could fund operational research or pilot studies (e.g. assessing new delivery strategies, diagnostics, or digital tools) to strengthen evidence for more efficient and scalable malaria control.
• This level of investment could train and equip hundreds of community health workers, improving early detection, proper treatment, and reducing pressure on health facilities. Strengthen community outreach and early detection in areas where malaria cases remain stubbornly high
• If an approach has demonstrated strong results — like community case management or improved testing — £100,000 could help scale it to additional districts, reaching thousands more people. 

This level of support helps stabilise and improve programmes that are already working but need more consistent resources. 

With an additional US$1,000,000 we could:  

• Scale up support for the rollout of the malaria vaccine across high burden countries across Africa
• Improve data systems and surveillance to increase understanding of child immunity and intervention impact in Africa
• Close immunisation gaps in West Africa, reaching zero-dose and under-immunised children with integrated services
• Expand preventive treatment to entirely new areas where the most underserved children are currently unprotected
• Build multi-year stability for some of our most effective work, enabling ministries of health and field teams to plan ahead
• Strengthen locally-led partnerships that strengthen monitoring, research, and delivery systems that improve long-term effectiveness 

At this scale, donors help change what is possible — extending protection to communities that would otherwise not receive support. 

In summary, every contribution — whether large or small — helps Malaria Consortium reach more children, strengthen communities, and deliver proven, cost-effective interventions where they are needed most. Flexible funding allows us to respond quickly to urgent needs, scale up what works, and invest in evidence and innovation to maximise impact and effectively evaluate it. Your support this giving season will not only sustain life-saving programmes but also enable us to expand our reach, strengthen health systems, and move closer to a future free from malaria. Together, we can turn nets, tests, vaccines, and treatments into real protection — and real lives saved. 

For more information reach out to Michelle Davis, Deputy Director, Philanthropy

partnerships@malariaconsortium.org 

www.malariaconsortium.org